Tina Stibbe

Tina Stibbe

Auto-generated profile, based on publicly available information

Tina Stibbe

PETA Deutschland e.V., Friolzheimer Strasse 3, 70499, Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTina Stibbe
Tina Stibbe
JHJue Huang
Jue Huang
MPMadlen Paucke
Madlen Paucke
CUChristine Ulke
Christine Ulke
MSMaria Strauß
Maria Strauß
The aim of this study was to assess cognitive differences between male and female adults with Attention Deficit Hyperactivity Disorder (ADHD). Patients with an ADHD diagnosis according to the DSM-IV guidelines were included in a cross-sectional study evaluating cognitive measures. 28 women and 41 men from ages 19 to 56 completed self-report questionnaires and performed a computer-based test of attentional performance (TAP). The TAP assesses cognitive functions highly affected in ADHD patients, including working memory, alertness and attention as well as behavioral control and response inhibition. There were no measurable differences in self-report scales assessing current symptomology between the sexes, however men scored higher on the scale for childhood symptoms. Performance measures for general wakefulness were comparable between men and women, while working memory and behavioral control test results differed. Females reacted significantly slower and more unstable for both the TAP Go/NoGo paradigm and working memory subtest, while also making more errors in the latter. We found gender-specific effects regarding working memory and behavioral control in this sample of adult patients with ADHD. Further studies are warranted, examining whether these differences relate to differences in clinical presentation and comorbidity patterns between men and women.

27 June 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
ETEmily R. Trunnell
Emily R. Trunnell
JBJulia Baines
Julia Baines
SFStephen Farghali
Stephen Farghali
TJTara Jackson
Tara Jackson
KJKimberley Jayne
Kimberley Jayne
TSTina Stibbe
Tina Stibbe
Depressive disorders are one of the most common mental disorders globally and progress in treating these disorders has been hampered, in part, by a lack of suitable nonclinical efficacy tests. Two common tests used in nonclinical efficacy studies of antidepressants-the forced swim test (FST) and tail suspension test (TST)-have come under criticism in recent years for their inconsistency and lack of validity, yet they continue to be used in the pharmaceutical industry. In this review, we provide a rationale for why international pharmaceutical regulatory and guidance agencies should begin issuing direction on methods for non-clinical efficacy testing that traditionally use the FST and TST, particularly considering that some regulators, such as those in the U.S. and E.U., allow the authorization of clinical trials to proceed without requiring tests in animals. The area of antidepressant drug discovery represents an important opportunity for reducing the attrition of psychiatric drugs, harmonizing regulatory requirements, and reducing animal use. Specific recommendations for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) have been provided.

14 September 2023 in EMBO Reports
Verified
Journal Article
Closed access
TSTina Stibbe
Tina Stibbe